Keryx Biopharmaceuticals Announces Participation in a Renal Disease Panel at the JMP Securities Life Sciences Conference on T...
20 Juin 2018 - 3:21PM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical
company focused on bringing innovative medicines to people with
kidney disease, today announced participating in an upcoming panel
in New York City.
- The JMP Securities Life Sciences Conference on Thursday, June
21st at 11:00 a.m. Eastern time: Keryx will be participating in a
50 minute panel discussion titled Renal Disease: Recent
Advancements and Future Prospects at The St. Regis New York Hotel
in New York City.
A live audio webcast of the panel discussion will be accessible
from Keryx’s website at http://investors.keryx.com within the
Investor Relations section under “events and presentations.” An
archived version of the webcast will be available for at least 15
days following the conclusion of the panel discussion.
About Keryx Biopharmaceuticals, Inc. Keryx
Biopharmaceuticals, Inc., headquartered in Boston, Massachusetts,
is focused on the development and commercialization of innovative
medicines that provide unique and meaningful advantages to people
with kidney disease. The Keryx team consists of approximately 200
committed people working with passion to advance the care of people
with this complex disease. This dedication has resulted in two
FDA-approved indications for Keryx’s first medicine, Auryxia
(ferric citrate) tablets. For more information about Keryx, please
visit www.keryx.com.
KERYX BIOPHARMACEUTICALS CONTACT
Amy Sullivan
Senior Vice President, Corporate Affairs
T: 617.466.3519
amy.sullivan@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
Real-Time news about Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ): 0 recent articles
Plus d'articles sur